PKS VIDEO LIBRARY
<< View complete library >>
NEWS from CONSORTIUM MEMBERS
Jefferson Health has named Brian Sweeney as president and chief operating officer of its New Jersey division. Sweeney, a 23-year Jefferson Health veteran, began his career as a registered nurse. He had been serving as interim president since early March when he took over the job previously held Joseph D. Devine.
Children's Hospital of Philadelphia once again grabbed the No. 2 spot on U.S. News and World Report's annual ranking of the country's best pediatric medical centers.
Young patients with no risk factors for stroke may have an increased risk if they have contracted COVID-19, whether or not they are showing symptoms of the disease. Surgeons at Thomas Jefferson University and collaborators analyzed patients presenting with stroke from March 20th until April 10th at their institutions. The strokes they observed were unlike what they usually see.
Michael Baram, MD, and other pulmonary researchers at Thomas Jefferson University partnered with the Jefferson Clinical Research Institute (JCRI) to get one of the first COVID-19 related clinical trials up and running in record time at Thomas Jefferson University.
The micronutrient zinc administered orally as zinc gluconate (an over-the-counter lozenge) may help to prevent cancer of the esophagus in patients diagnosed with the pre-malignant condition called Barrett’s esophagus (BE), according to the results of a first-ever pilot study in humans conducted, in part, by investigators at the Lankenau Institute for Medical Research (LIMR) and physicians at the Lankenau Medical Center.
Professor of Evolutionary Genomics Sergei Pond is on the lookout for mutations in the DNA of the coronavirus.
A new study involving researchers from Children’s Hospital of Philadelphia has identified immune biomarkers in patients with acute myeloid leukemia (AML) that can help predict which patients will be resistant to chemotherapy and which might benefit from a new immunotherapy.
The COVID-19 pandemic has disrupted the lives of adolescents in many ways, including missing or delaying important milestones.
Scientists at The Wistar Institute developed a synthetic DNA approach that instructs in vivo production of a human monoclonal antibody able to neutralize hepatitis B virus (HBV) and prevent infection of liver cells in vitro.
Research assistant professor Ami Patel has spent her career committed to using novel engineering approaches to fight harmful infectious diseases.
If you want to stay informed about BioStrategy Parterns, subscribe here.
email@example.comP.O. Box 83 Boiling Springs, PA 17007
2017, BioStrategy Partners. All rights reserved